Jeffrey Eisele, Chief Development Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 303 shares at $60.23 ($18K) on 2023-12-27, disclosed to the SEC on 2023-12-28.
Scheduled sale ($18k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $57.86 | 68 | $4K | 21.8% |
| 2 | $60.23 | 235 | $14K | 78.2% |
| Total | $59.70 avg | 303 | $18K | 100% |
| Filing → |
| APLS | SELL | 2025-01-14 | $8K | — | Filing → |
| APLS | SELL | 2024-12-27 | $2K | — | Filing → |
| APLS | SELL | 2024-01-31 | $145K | — | Filing → |